Current Edition


Biogen, struggling to sell Alzheimer’s drug, begins layoffs to save money

Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes …

Continue Reading →

For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory

In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the …

Continue Reading →